# US 8,278,338 B2 · Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,338 B2
- Document ID: US8278338B2
- Status: Granted
- Kind: B2
- Application number: 11/643,792
- Filed: 2006-12-22
- Published: 2007-08-30
- Granted: 2012-10-02
- Earliest claimed: 2004-06-22
- Assignees: Gruenenthal GmbH
- Inventors: Bernd Sundermann; Hagen-Heinrich Hennies; Klaus Schiene; Petra Bloms-Funke; Werner Englberger; Sven Frormann; Derek Saunders
- Web page: https://patentgrep.com/patent/US8278338B2

## CPC

- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07D 213/38: having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines=compounds corresponding to formula (I), wherein the various substituents have the meaning provided in the description, and pharmaceutical formulations containing these compounds and methods for producing these compounds and related pharmaceutical formulation, and to methods for treating or inhibiting pain, depression and/or anxiety states.

## Claims

### Claim 1

A saturated or unsaturated 3-pyridyl-benzocycloalkylmethyl-amine compound corresponding to formula I
wherein
W is CH2, and n=from 0 to 3,
R1 and R2, independently of one another, are selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR3′, where
R3′ is selected from
H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl, mono- or poly-substituted or unsubstituted;
or
R1 and R2 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR4′, where
R4′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
and
R3 to R6, independently of one another, are selected from H or any radicals selected from the group consisting of
F, Cl, Br, I, CN, CF3, OCF3, NO2, C1-C10-alkyl, C2-C10-alkenyl and C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR5′, where
R5′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
OR6′, OC(O)R6′, OC(S)R6′, C(O)R6′, C(O)OR6′, C(S)R6′, C(S)OR6′, SR6′, S(O)R6′ or S(O2)R6′, where
R6′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR7, where
R7 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
NR8R9, C(O)NR8R9 or S(O2)NR8R9 wherein
R8 and R9, independently of one another, are selected from H, C1-C18-alkyl, C2-C18-alkenyl or C3-C18-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
or
R8 and R9 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted,
and
Y is selected from H and OH when X is simultaneously H, or
X and Y together form a bond,
wherein mono- or poly-substituted means the replacement of one or more hydrogens with one or more substituents selected from the group consisting of F, Cl, Br, I, NH2, SH, OH, and OCH3;
optionally in the form of an isolated enantiomer or isolated diastereomer or an optionally racemic mixture of stereoisomers;
or a salt thereof with physiologically acceptable acid.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is present in the form of a salt with physiologically acceptable acid.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is present in the form of an isolated enantiomer or isolated diastereoisomer.

### Claim 4 (depends on 1)

The compound of claim 1, wherein said compound is present in the form of a mixture of stereoisomers.

### Claim 5 (depends on 4)

The compound of claim 4, wherein said compound is present in the form of a racemic mixture.

### Claim 6 (depends on 1)

The compound of claim 1, wherein n<3.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
W═CH2,
n<3,
R1 and R2 each=methyl, and
R5 and R6 each=H.

### Claim 8 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
2-dimethylaminomethyl-1-pyridin-3-yl-indan-1-ol and the corresponding hydrochloride;
dimethyl-(3-pyridin-3-yl-1H-inden-2-ylmethyl)-amine and the corresponding hydrochloride;
dimethyl-(1-pyridin-3-yl-indan-2-ylmethyl)-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-5-methoxy-1-pyridin-3-yl-indan-1-ol and the corresponding hydrochloride;
(6-methoxy-3-pyridin-3-yl-1H-inden-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-1-pyridin-3-yl-3H-inden-5-ol and the corresponding hydrochloride;
2-dimethylaminomethyl-1-pyridin-3-yl-1,2,3,4-tetrahydro-naphthalen-1-ol and the corresponding hydrochloride;
dimethyl-(1-pyridin-3-yl-3,4-dihydro-naphthalen-2-ylmethyl)-amine and the corresponding hydrochloride;
dimethyl-(1-pyridin-3-yl-1,2,3,4-tetrahydro-naphthalen-2-ylmethyl)-amine and the corresponding hydrochloride;
6-dimethylaminomethyl-5-pyridin-3-yl-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol and the corresponding hydrochloride;
dimethyl-(5-pyridin-3-yl-8,9-dihydro-7H-benzocyclohepten-6-ylmethyl)-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-5-fluoro-1-pyridin-3-yl-indan-1-ol and the corresponding hydrochloride;
(6-fluoro-3-pyridin-3-yl-1H-inden-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-1-pyridin-3-yl-5-trifluoromethoxy-indan-1-ol and the corresponding hydrochloride;
dimethyl-(3-pyridin-3-yl-6-trifluoromethoxy-1H-inden-2-ylmethyl)-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-1-pyridin-3-yl-5-trifluoromethyl-indan-1-ol and the corresponding hydrochloride;
dimethyl-(3-pyridin-3-yl-6-trifluoromethyl-1H-inden-2-ylmethyl)-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-6-methoxy-1-pyridin-3-yl-indan-1-01 and the corresponding hydrochloride;
(5-methoxy-3-pyridin-3-yl-1H-inden-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride;
2-di methylaminomethyl-5-methoxy-1-pyridin-3-yl-1,2,3,4-tetrahydro-naphthalen-1-ol and the corresponding hydrochloride;
(5-methoxy-1-pyridin-3-yl-3,4-dihydro-naphthalen-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride, and
6-dimethylaminomethyl-5-pyridin-3-yl-7,8-dihydro-naphthalen-1-ol and the corresponding hydrochloride.

### Claim 9 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
dimethyl-(3-pyridin-3-yl-1H-inden-2-ylmethyl)-amine and the corresponding hydrochloride;
(6-methoxy-3-pyridin-3-yl-1H-inden-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride;
2-dimethylaminomethyl-1-pyridin-3-yl-3H-inden-5-ol and the corresponding hydrochloride;
6-dimethylaminomethyl-5-pyridin-3-yl-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol and the corresponding hydrochloride;
dimethyl-(5-pyridin-3-yl-8,9-dihydro-7H-benzocyclohepten-6-ylmethyl)-amine and the corresponding hydrochloride;
(6-fluoro-3-pyridin-3-yl-1H-inden-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride;
dimethyl-(3-pyridin-3-yl-6-trifluoromethoxy-1H-inden-2-ylmethyl)-amine and the corresponding hydrochloride;
(5-methoxy-1-pyridin-3-yl-3,4-dihydro-naphthalen-2-ylmethyl)-dimethyl-amine and the corresponding hydrochloride, and
6-dimethylaminomethyl-5-pyridin-3-yl-7,8-dihydro-naphthalen-1-01 and the corresponding hydrochloride.

### Claim 10

A process for preparing a saturated or unsaturated 3-pyridyl-benzocycloalkylmethyl-amine compound corresponding to formula I
wherein
W is CH2, and n=from 0 to 3,
R1 and R2, independently of one another, are selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR3′, where
R3′ is selected from
H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl, mono- or poly-substituted or unsubstituted;
or
R1 and R2 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR4′, where
R4′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
and
R3 to R6, independently of one another, are selected from H or any radicals selected from the group consisting of
F, Cl, Br, I, CN, CF3, OCF3, NO2, C1-C10-alkyl, C2-C10-alkenyl and C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR5′, where
R5′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
OR6′, OC(O)R6′, OC(S)R6′, C(O)R6′, C(O)OR6′, C(S)R6′, C(S)OR6′, SR6′, S(O)R6′ or S(O2)R6′, where
R6′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR7, where
R7 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
NR8R9, C(O)NR8R9 or S(O2)NR8R9 wherein
R8 and R9, independently of one another, are selected from H, C1-C18-alkyl, C2-C18-alkenyl or C3-C18-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
or
R8 and R9 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted,
and
Y is selected from H and OH when X is simultaneously H, or
X and Y together form a bond,
wherein mono- or poly-substituted means the replacement of one or more hydrogens with one or more substituents selected from the group consisting of F, Cl, Br, I, NH2, SH, OH, and OCH3;
or a salt thereof with physiologically acceptable acid,
said process comprising the steps of:
reacting a cycloalkanone of formula II with an immonium salt of formula III or with paraformaldehyde and an amine of formula IV, wherein R10 has a meaning analogous to R1 and R11 has a meaning analogous to R2,
reacting the resulting Mannich bases with an organometallic compound of formula V in which Z represents Li, in solvents at a temperature of from −70° C. to 60° C., wherein, in the case where either R10 or R11 is hydrogen or R10 and R11 are simultaneously hydrogen, compounds of formula III or IV in which R10 or R11 or R10 and R11 represent a benzyl radical are used in the Mannich reaction, which benzyl radical is removed by catalytic reaction with hydrogen, and wherein compounds of formula V in which Z represents lithium or magnesium halide are prepared by halogen-lithium exchange by reaction of halogen compounds of formula VI in which A is Cl, Br or I, or compounds of formula V are reacted with compounds of formula II in the presence of cerium(II) halide, to yield products of the general formula VII wherein R10 has a meaning analogous to R1 and R11 has a meaning analogous to R2, which products are reacted with thionyl chloride and then subjected to basic working up to form compounds of formula IX or a mixture of compounds of formulas VIII and IX wherein R10 has a meaning analogous to R1 and R11 has a meaning analogous to R2, the compounds are separated, or
preparing compounds of formula IX by reacting compounds of formula VII with strong acids, then hydrogenolytically cleaving compounds of formula VIII or hydrogenating compounds of formula IX wherein R10 has a meaning analogous to R1 and R11 has a meaning analogous to R2 by catalytic reaction with hydrogen in solvents at pressures of from 0.1 to 10 bar and temperatures of from 20° C. to 80° C., to form compounds of formula X wherein R10 has a meaning analogous to R1 and R11 has a meaning analogous to R2.

### Claim 11 (depends on 10)

The process of claim 10, wherein said halogen-lithium exchange is performed with a solution of n-butyllithium and hexane.

### Claim 12 (depends on 10)

A process according to claim 10, wherein at least one OH group present in formula I is replaced by an OSi(Ph)2tert.but, group, at least one SH group is replaced by a S-p-methoxybenzyl group and/or at least one NH2 group is replaced by an NO2 group and, when the entire reaction sequence is complete, removing a OSi(Ph)2tert.but, group with tetrabutylammonium fluoride in tetrahydrofuran and/or removing at least one p-methoxybenzyl group with a metal amine, and/or reducing at least one NO2 group to NH2.

### Claim 13 (depends on 12)

The process of claim 12, wherein said metal amine is sodium amine.

### Claim 14 (depends on 11)

A process according to claim 11, wherein after the butyllithium reaction, the process further comprises the step of saponifying at least one C(O)OCH3 and/or a C(S)OCH3 group using KOH solution or NaOH solution in methanol at a temperature of from 40° C. to 60° C.

### Claim 15

A pharmaceutical formulation comprising as an active ingredient one or more compounds corresponding to formula I
wherein
W is CH2, and n=from 0 to 3,
R1 and R2, independently of one another, are selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR3′, where
R3′ is selected from
H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl, mono- or poly-substituted or unsubstituted;
or
R1 and R2 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR4′, where
R4′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
and
R3 to R6, independently of one another, are selected from H or any radicals selected from the group consisting of
F, Cl, Br, I, CN, CF3, OCF3, NO2, C1-C10-alkyl, C2-C10-alkenyl and C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR5′, where
R5′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
OR6′, OC(O)R6′, OC(S)R6′, C(O)R6′, C(O)OR6′, C(S)R6′, C(S)OR6′, SR6′, S(O)R6′ or S(O2)R6′, where
R6′ is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR7, where
R7 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
NR8R9, C(O)NR8R9 or S(O2)NR8R9 wherein
R8 and R9, independently of one another, are selected from H, C1-C18-alkyl, C2-C18-alkenyl or C3-C18-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted; C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, saturated or unsaturated, mono- or poly-substituted or unsubstituted; aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted;
or
R8 and R9 together form a C3-C7-cycloalkyl, saturated or unsaturated, mono- or poly-substituted or unsubstituted, or a corresponding heterocycle in which a carbon atom in the ring has been replaced by S, O or NR10, where
R10 is selected from H, C1-C10-alkyl, C2-C10-alkenyl or C3-C10-alkynyl, in each case branched or unbranched, mono- or poly-substituted or unsubstituted;
alkylaryl, aryl or 5- or 6-membered heteroaryl aromatic rings containing 1 or 2 heteroatoms selected from the group consisting of O, N and S, in each case mono- or poly-substituted or unsubstituted,
and
Y is selected from H and OH when X is simultaneously H, or
X and Y together form a bond,
wherein mono- or poly-substituted means the replacement of one or more hydrogens with one or more substituents selected from the group consisting of F, Cl, Br, I, NH2, SH, OH, and OCH3;
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable auxiliary substance.

### Claim 16 (depends on 1)

A method for the treatment or inhibition of pain, depression and/or anxiety in a mammal, said method comprising the step of administering to said mammal a pharmaceutically effective amount of a compound corresponding to formula I of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method for the treatment or inhibition of a condition selected from the group consisting of migraine, urinary incontinence, fibromyalgia, eating disorders, bulimia, hyperactivity, drug dependency, addiction or withdrawal, trichotillomania, Tourette's syndrome, skin, psychoses, memory disorders, cognitive disorders and Alzheimer's disease in a mammal, said method comprising the step of administering to said mammal a pharmaceutically effective amount of a compound corresponding to formula I of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said skin disorder is post-herpetic neuralgia or pruritus.
